AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph at page 1, lines 1-2 with the following:

--This application is a continuation of U.S. Patent Application No. 09/132,213, filed August 11, 1998 (abandoned), which is a continuation of 08/316,415, filed September 30, 1994 (U.S. Patent No. 5,824,469), which is a continuation of 08/105,108, filed August 11, 1993 (abandoned), which is a continuation of 07/881,607, filed May 12, 1992 (abandoned), which is a continuation of 07/368,674, filed June 19, 1989 (abandoned), which is a continuation-in-part of U.S. Patent Application No. 06/887,970, filed July 17, 1986 (abandoned). The entire contents of the foregoing applications are incorporated herein by reference in their entireties.--

Please replace the paragraph at page 30, lines 11-24 with the following:

--Synthesis of Random Oligonucleotides. The double-stranded oligonucleotide used in the construction of the nonproducer strain, pBNP, was synthesized by hybridizing 200 ng of 9-mer primer, 5'AGCAGTACT-3', to 1 μg of the single-stranded oligonucelotide template, 5'-CGCCCCGAGGAACGT (N)23 AGTACT-GCT-3' (SEQ ID NO: 10), in 20 mM Tris-HC1 9pH 7.5), 10 mM $MgCl_2$, 50 mM NaCl, and 1 mM dithiothreitol at 65°C for 10 min. This template-primer was extended with the large fragment of *E. coli* Pol I, digested with *Ava* I and *Sca* I and purified by polyacylamide gel electrophoresis. The double-stranded oligonucleotide for the construction of the plasmid used in selecting new mutants was synthesized by a similar protocol: 200 ng of 9-mer primer 5'AGCAGTACT-3' was hybridized to 1 μg of the template oligonucleotide:

5'-CGCCCCGAGGAACGTTTT $(N)_9$ AGC $(N)_6$ AAAGTACTGCT-3' (SEQ ID NO: 11). The template-primer was extended with *E. coli* Pol I, digested with *Ava* I and *Sca* I, and used as a replacement for the insert in the nonproducer strain.--

Please insert the attached paper copy of the Sequence Listing between page 37 of the specification, and page 38 which contains the claims.